CLL · Oncology · 5 drugs · 4 indications
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|---|---|---|---|---|
| Jaypirca | LLY | BTK inhibitor (non-covalent) | Small molecule | ORAL | APPROVED |
| Rituxan/MabThera | ROG.SW | CD20 antagonist | Antibody | IV | APPROVED |
| Calquence | AZN | BTK inhibitor | Small molecule | ORAL | APPROVED |
| Imbruvica | ABBV | BTK inhibitor | Small molecule | PO | APPROVED |
| Venclexta | ABBV, ROG.SW | BCL-2 inhibitor | Small molecule | PO | APPROVED |